This clinical trial is focused on studying the effectiveness of two treatments for Rheumatoid Arthritis (RA), a condition that causes pain and swelling in the joints. The treatments being compared are Abatacept and Adalimumab, both of which are given as injections under the skin. These medications are used alongside another drug called methotrexate, which is commonly prescribed for RA. The study aims to determine which treatment is more effective in improving the symptoms of RA in patients who have not responded well to methotrexate alone.

Participants in the study will receive either Abatacept or Adalimumab, in addition to their regular methotrexate treatment. The study will last for several months, during which time the participants’ response to the treatment will be monitored. The main goal is to see if one of the treatments leads to a better improvement in joint symptoms by the end of the study period. The study is designed to be single-blind, meaning that the participants will not know which treatment they are receiving, but the researchers will.

This trial is particularly focused on individuals with early-stage RA who have specific genetic markers known as “shared epitope” HLA Class II risk alleles. These markers are associated with a higher risk of developing RA. The study will assess the effectiveness of the treatments in achieving a significant reduction in RA symptoms, as measured by a standard clinical response called ACR50, which indicates a 50% improvement in symptoms. The results will help determine the best treatment option for patients with this type of RA.